Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Anticoagulants are the drugs used for prevention of blood clotting in the patients suffering from bleeding disorders such as Hemophilia A, Hemophilia B, and Von Willebrand diseases. Vitamin K antagonists such as phenprocoumon and warfarin are few of the most commonly used oral anticoagulatory agents. Non-vitamin K antagonist oral anticoagulants (NOACs) are rivaroxaban and dabigatran. Anticoagulant reversal drugs works as reversal agents of anticoagulation and are needed due to life-threatening or uncontrolled bleeding.

The global anticoagulant reversal drugs market is estimated to be valued at US$ 1,154.3 million in 2021 and is expected to exhibit a CAGR of 15.1% over the forecast period (2021-2028).

Figure 1. Global Anticoagulant Reversal Drugs Market Share (%), By Region, 2021

Anticoagulant Reversal Drugs  | Coherent Market Insights

The increasing prevalence of bleeding disorders is expected to drive the growth of the global anticoagulant reversal drugs market over the forecast period.

Rising prevalence of bleeding disorders such as hemophilia is expected to boost the anticoagulant therapy and thereby driving the global anticoagulant reversal drugs market growth over the forecast period. For instance, according to the Annual Global Survey’s 2019 data published by World Federation of Hemophilia, around 210,454 number of people globally were suffering from hemophilia in 2018. Among this, 173,711 and 34,289 patients accounted for Hemophilia A and Hemophilia B, respectively.

request-sample

Anticoagulant Reversal Drugs Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 1,154.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2021 to 2028 CAGR: 15.1% 2028 Value Projection: US$ 3,089.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine, Others
  • By Distribution Channel: Hospital Pharmacies , Retail Pharmacies, Online Pharmacies
Companies covered:

Alexion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Behring Limited, Pfizer Inc., Octapharma AG, Bausch Health Companies Inc., Amneal Pharmaceuticals Inc., Fresenius Kabi AG, Perosphere Pharmaceuticals Inc., Ferring Pharmaceuticals Inc., Midas Pharma GmbH, Healthy Life Pharma Pvt. Ltd, Pharma Cure Laboratories, AMAG Pharmaceuticals, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., and Nischi Lifesciences

Growth Drivers:
  • Increasing prevalence of bleeding disorders
  • Rising prevalence of cardiovascular diseases
  • Increasing product launches by market players
  • Increasing strategic collaborations among the market players
Restraints & Challenges:
  • Rising product recalls

Figure 2. Global Anticoagulant Reversal Drugs Market Value (US$ Mn), By Drug Type, 2021

Anticoagulant Reversal Drugs  | Coherent Market Insights

The increasing research and development activities for the development of novel therapeutics as an antidote of coagulant drugs is expected to drive the market growth over the forecast period.

The rising number research and development activities by the market players in order to develop novel drugs is expected to drive the growth of the global anticoagulant reversal drugs market over the forecast period.

For instance, in July 2020, Janssen Research and Development LLC initiated the Phase I clinical trial study to assess the Reversal of the Anticoagulant Effects of JNJ-70033093 by 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa (rFVIIa). The study is estimated to complete by October 2021.

Global Anticoagulant Reversal Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020.

According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 190,169,833 cases and 4,086,000 deaths due to coronavirus disease (COVID-19) were reported till July 18, 2021, across the globe.

During this COVID-19 pandemic, pharmaceutical business, clinical tool companies, and likewise biotechnology firms are facing difficulties that are occurring from the interruption in supply chains and the demand to transform service processes. The COVID-19 pandemic has negatively impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. However, the demand for anticoagulant reversal drugs is expected to increase in this COVID-19 pandemic owing to rising demand for the anticoagulant therapy.

The COVID-19 impact on the anticoagulant reversal drugs market is expected to be positive owing to the association of COVID-19 infection with blood disorders. For instance, according to a research article published in the American Journal of Hematology, 2020, it was observed that the COVID-19 positive patients who were suffering from severe complications exhibited increased levels of protein Factor V, a blood-clotting factor. Increased levels of protein Factor V could lead to the development of blood clots in various vital organs inside the human body.

Global Anticoagulant Reversal Drugs Market - Restraint

However, recall of the drugs by the market players is the major factor restraining the global anticoagulant reversal drugs market over the forecast period. For instance, in March 2020, Dr. Reddy’s Laboratories Ltd. announced the voluntary recall of four lots (ACB902, ACB903, ACB904, and ACB905) of Phytonadione Injectable Emulsion USP, 10 mg/mL. The product is being recalled due to product complaints received due to ampules breaking and shattering, upon opening, during compounding. Phytonadione, is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX, and X when caused by Vitamin K deficiency or interference with Vitamin K activity and for anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives.

Key Players

Major players operating in the global anticoagulant reversal drugs market include Alexion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Behring Limited, Pfizer Inc., Octapharma AG, Bausch Health Companies Inc., Amneal Pharmaceuticals Inc., Fresenius Kabi AG, Perosphere Pharmaceuticals Inc., Ferring Pharmaceuticals Inc., Midas Pharma GmbH, Healthy Life Pharma Pvt. Ltd, Pharma Cure Laboratories, AMAG Pharmaceuticals, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., and Nischi Lifesciences

Anticoagulants are used for treating and preventing blood clots events.  Phenprocoumon and warfarin are the most commonly used oral anticoagulant agents. Phenprocoumon and warfarin are categorized as vitamin K antagonists while rivaroxaban and dabigatran are categorized as non-vitamin K antagonist oral anticoagulants (NOACs). Vitamin K antagonists work by inhibiting the enzyme vitamin K epoxide reductase which leads to blockage of the hepatic synthesis of the active, reduced form of vitamin K. This reduced form of vitamin K is required for carboxylation of protein C, protein S, and coagulation factors II, VII, IX, and X. Non-vitamin K antagonist oral anticoagulants work in a selective manner by either inhibiting factor Xa (rivaroxaban, apixaban, edoxaban) or thrombin (dabigatran). Since, NOACs have a comparatively short half-life and fewer interactions, NOACs are easier to control and administer than warfarin and do not require regular monitoring to ensure their efficacy and safety. Anticoagulant reversal drugs work opposite to that of anticoagulation drugs by canceling out its anticoagulation effects and are needed to control life-threatening bleeding.

Market Dynamics

Increasing prevalence of cardiac events such as ischemic stroke, pulmonary embolism, deep vein thrombosis, and others which require anticoagulant therapy is expected to fuel the global anticoagulant reversal drugs market. For instance, according to an article published by the National Centers for Biotechnology Information in July 2020, there is an increasing prevalence of Ischemic heart disease across the globe, as it affects 1,655 per 100,000 individuals, which may rise up to 1,845 per 100,000 individuals by the year 2030. Furthermore, according to data provided by the American College of Cardiology Foundation, it was estimated that around 1.05 million people suffered from coronary diseases in the U.S. in 2019. Moreover, according to the Centers for Disease Control and prevention (CDC) report 2020, it is estimated that more than 800,000 people in the U.S. suffer from a heart attack every year.

Rising collaboration and acquisition activities by the market players is expected to drive the global anticoagulant reversal drugs market. For instance, in April 2016, Daiichi Sankyo Company, Limited announced a clinical collaboration agreement with Portola Pharmaceuticals, Inc. for the development of andexanet alfa in Japan as an anticoagulant reversal agent for Daiichi Sankyo's Factor Xa inhibitor, LIXIANA (edoxaban).

Key features of the study:

  • This report provides in-depth analysis of the global anticoagulant reversal drugs  market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global anticoagulant reversal drugs  market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Alexion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Behring Limited, Pfizer Inc., Octapharma AG, Bausch Health Companies Inc., Amneal Pharmaceuticals Inc., Fresenius Kabi AG, Perosphere Pharmaceuticals Inc., Ferring Pharmaceuticals Inc., Midas Pharma GmbH, Healthy Life Pharma Pvt. Ltd, Pharma Cure Laboratories, AMAG Pharmaceuticals, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., and Nischi Lifesciences
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global anticoagulant reversal drugs  market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticoagulant reversal drugs market

Detailed Segmentation:

  • Global Anticoagulant Reversal Drugs Market, By Drug Type:
    • Prothrombin Complex Concentrates
    • Phytonadione
    • Andexanet Alfa
    • Idarucizumab
    • Protamine
    • Others
  • Global Anticoagulant Reversal Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • Global Anticoagulant Reversal Drugs Market, By Region:
    • North America
      • By Drug Type
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Idarucizumab
        • Protamine
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Type
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Idarucizumab
        • Protamine
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Idarucizumab
        • Protamine
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Idarucizumab
        • Protamine
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Idarucizumab
        • Protamine
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Prothrombin Complex Concentrates
        • Phytonadione
        • Andexanet Alfa
        • Idarucizumab
        • Protamine
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Alexion Pharmaceuticals, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Boehringer Ingelheim GmbH
    • CSL Behring Limited
    • Pfizer Inc.
    • Octapharma AG
    • Bausch Health Companies Inc.
    • Amneal Pharmaceuticals Inc.
    • Fresenius Kabi AG
    • Perosphere Pharmaceuticals Inc.
    • Ferring Pharmaceuticals Inc.
    • Midas Pharma GmbH
    • Healthy Life Pharma Pvt. Ltd
    • Pharma Cure Laboratories
    • AMAG Pharmaceuticals, Inc.
    • SGPharma Pvt. Ltd.
    • Alps Pharmaceutical Ind. Co., Ltd.
    • Nischi Lifesciences

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • PEST Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Highlights
    • Reimbursement Scenario
    • Mergers & Acquisitions
  4. Global Anticoagulant Reversal Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • Impact on Clinical Trials and Drug Development
    • Government Initiatives
  5. Global Anticoagulant Reversal Drugs Market, By Drug Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Prothrombin Complex Concentrates
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Phytonadione
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Andexanet Alfa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Idarucizumab
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Protamine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  6. Global Anticoagulant Reversal Drugs Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Anticoagulant Reversal Drugs  Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2028
    • North America
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Region/Country, 2017 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Alexion Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CSL Behring Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Octapharma AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bausch Health Companies Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amneal Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Fresenius Kabi AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Perosphere Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ferring Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Midas Pharma GmbH
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Healthy Life Pharma Pvt. Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pharma Cure Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AMAG Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • SGPharma Pvt. Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Alps Pharmaceutical Ind. Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Nischi Lifesciences
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 32 market data tables and 21 figures on "Anticoagulant Reversal Drugs Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global anticoagulant reversal drugs market size is estimated to be valued at US$ 1,154.3 million in 2021 and is expected to exhibit a CAGR of 15.1% between 2021 and 2028.
Increasing number of anticoagulant reversal drugs product launches, rising cases of bleeding disorders and cardiovascular diseases, increasing research and development activities by the market players, and increasing strategic collaborations among the market players are some of the driving factors, which are expected to drive growth of the market.
Andexanet alfa segment is expected to hold the major market share, owing to favourable reimbursement scenario during the forecast period.
North America holds the largest market share in the market.
Major factor hampering growth of the market is increasing product recalls.
Major players operating in the market include Alexion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Behring Limited, Pfizer Inc., Octapharma AG, Bausch Health Companies Inc., Amneal Pharmaceuticals Inc., Fresenius Kabi AG, Perosphere Pharmaceuticals Inc., Ferring Pharmaceuticals Inc., Midas Pharma GmbH, Healthy Life Pharma Pvt. Ltd, Pharma Cure Laboratories, AMAG Pharmaceuticals, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., and Nischi Lifesciences
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.